期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Plasma cell leukemia-one in a million: A case report 被引量:2
1
作者 Akriti Gupta Jain Mohammed Faisal-Uddin +3 位作者 Abdul K Khan Mohammed Wazir Qi Shen Manoucher Manoucheri 《World Journal of Clinical Oncology》 2019年第3期161-165,共5页
BACKGROUND Plasma cell leukemia(PCL) is diagnosed by the presence of an absolute plasma cell count of > 2 × 109/L or 20% plasma cells in the peripheral blood. Because the incidence of PCL is relatively low, ou... BACKGROUND Plasma cell leukemia(PCL) is diagnosed by the presence of an absolute plasma cell count of > 2 × 109/L or 20% plasma cells in the peripheral blood. Because the incidence of PCL is relatively low, our case report study presents a rare opportunity to describe the clinical and pathological characteristics of this leukemia, as well as different modalities of treatment and outcomes of primary PCL(pPCL).CASE SUMMARY A 56-year-old male with a history of hypertension complained of pain in the left flank area which started four months prior to admission. On admission, his vital signs were stable, and physical examination was completely benign. Laboratory evaluation showed hemoglobin of 5.1 g/dL, white blood cell count of 6.6 cells per cubic millimeter with 16% atypical lymphocytes, and platelet count of 51000 per microliter. Peripheral smear showed more than 10%-15% of plasma cells(Figure1), and flow cytometry of peripheral blood confirmed PCL with 24% plasma cells CD138+. Bone marrow biopsy demonstrated 80% plasma cells(38+, 138+, 117+,10-, 19-, 20-, 56-) with 90% cellularity. The Oncology team was consulted, and VCD therapy was started. After completing therapy at 1, 4, 8, and 11 d, the patient was discharged home. The patient was being considered for a bone marrow transplant evaluation within two months of discharge.CONCLUSION PCL is a rare and aggressive form of leukemia with a poor prognosis. Multicenter studies and clinical trials should be conducted to develop accurate criteria for the initial diagnosis and prompt treatment of this disease. 展开更多
关键词 Primary plasma cell leukemia Case report Rare leukemia secondary plasma cell leukemia ALLOGENIC TRANSPLANTATION Chemotherapy
下载PDF
硼替佐米对治疗继发性浆细胞白血病患者血清M蛋白及临床疗效影响
2
作者 江荣科 车瑛琦 +2 位作者 任云会 李文庆 张丽丽 《中国生化药物杂志》 CAS 2017年第5期311-312,315,共3页
目的评价硼替佐米对治疗继发性浆细胞白血病患者血清M蛋白及临床疗效影响研究。方法 20例继发性浆细胞白血病患者随机分为对照组及试验组;对照组9例,给予醋酸泼尼松龙片,60 mg/(m2·d),口服,d1~d4+马法兰片,8 mg/(m^2·d)... 目的评价硼替佐米对治疗继发性浆细胞白血病患者血清M蛋白及临床疗效影响研究。方法 20例继发性浆细胞白血病患者随机分为对照组及试验组;对照组9例,给予醋酸泼尼松龙片,60 mg/(m2·d),口服,d1~d4+马法兰片,8 mg/(m^2·d),口服,d1~d4+沙利度胺,100~200 mg/d,口服,睡前;试验组11例,在对照组基础上加用注射用硼替佐米,1.3 mg/(m^2·d),静脉推注,d1、d4、d8、d11。比较2组患者治疗前后骨髓浆细胞比例、血清M蛋白(IgA、IgG)水平、治疗有效率及安全性。结果治疗后,与对照组比较,试验组患者浆细胞比例、M蛋白水平较低(P〈0.05)。试验组的治疗有效率(54.55%)显著高于对照组(11.11%)(P〈0.05),其结果均有统计学意义。结论硼替佐米能够显著降低继发性浆细胞白血病患者的骨髓浆细胞比例及血清M蛋白水平,提高临床疗效,且安全性较高。 展开更多
关键词 硼替佐米 继发性浆细胞白血病 临床疗效 安全性
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部